Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2023 - Breast Cancer
AMCP Nexus 2022
ASCO 2022 - Wrap Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2017
February 2017, Vol 8, No 1
February 2017, Vol 8, No 1
HIV Drug Shows Promise in Refractory Multiple Myeloma
By
Charles Bankhead
Hematologic Malignancies
,
Multiple Myeloma
February 2017, Vol 8, No 1
San Diego, CA—Nelfinavir (Viracept), a drug used for HIV, led to a surprisingly high response rate when added to bortezomib (Velcade) in patients with proteasome inhibitor–refractory multiple myeloma, according to a phase 2 study reported by Christoph Driessen, MD, myeloma specialist, Kantonsspital St. Gallen, Switzerland, at the 2016 American Society of Hematology meeting.
Read Article
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in CML
By
Phoebe Starr
Leukemia
February 2017, Vol 8, No 1
San Diego, CA—Although tyrosine kinase inhibitors (TKIs) including imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel), have dramatically improved outcomes in patients with chronic myeloid leukemia (CML), the costs of these drugs have spiraled out of control, causing some patients to stop treatment or cut their dosage because of financial toxicity. Data presented at the 2016 American Society of Hematology meeting show that it is possible for some patients with CML to reduce their TKI dose by 50% and maintain remission, perhaps even stop treatment altogether once deep and durable remission has been achieved after approximately 5 years of treatment.
Read Article
Lenalidomide Maintenance Therapy Extends Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia
By
Wayne Kuznar
Leukemia
February 2017, Vol 8, No 1
San Diego, CA—Maintenance therapy with lenalidomide (Revlimid) after frontline chemotherapy markedly prolonged progression-free survival (PFS) in patients with high-risk chronic lymphocytic leukemia (CLL), according to interim results from a phase 3 study presented at the 2016 American Society of Hematology meeting.
Read Article
Ponatinib, a Tyrosine Kinase Inhibitor, Active in Patients with Relapsed or Refractory Chronic Myeloid Leukemia and BCR-ABL T315I Mutation
By
Charles Bankhead
Leukemia
February 2017, Vol 8, No 1
San Diego, CA—Targeting a second-generation tyrosine kinase inhibitor (TKI) in mutation-specific chronic myeloid leukemia (CML) led to deep and durable responses that were maintained beyond 3 years in some cases, reported Neil Shah, MD, PhD, Department of Medicine/Hematology-Oncology, University of California San Francisco, during a poster presentation at the 2016 American Society of Hematology meeting.
Read Article
CPX-351 Improves Posttransplant Survival in Older Patients with High-Risk Acute Myeloid Leukemia
By
Phoebe Starr
Leukemia
February 2017, Vol 8, No 1
San Diego, CA—Induction therapy with a liposomal formulation of cytarabine and daunorubicin CPX-351 (Vyxeos) is superior to cytarabine plus daunorubicin (7+3 regimen) in patients with acute myeloid leukemia (AML), according to a subgroup analysis of a large phase 3 clinical trial that was presented at the 2016 American Society of Hematology (ASH) meeting.
Read Article
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
February 2017, Vol 8, No 1
Read Article
Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value
By
James T. Kenney, RPh, MBA
Payer’s Perspective
,
Value Peer-spectives
February 2017, Vol 8, No 1
The 2016 American Society of Hematology (ASH) meeting provided insight into new treatment options and mechanism of action choices for hematologic cancers. Health plans need to continue to expand their knowledge and expertise in all cancer types to maintain the ability to manage and apply coverage criteria appropriately as FDA approvals continue to increase in oncology.
Read Article
Induction Therapy plus Autologous Stem-Cell Transplantation Still Cost-Effective for Newly Diagnosed Multiple Myeloma
By
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
San Diego, CA—Although considered a standard of care for patients with newly diagnosed multiple myeloma, the benefit of autologous stem-cell transplantation (ASCT) has been recently questioned as a result of the rapid expansion of novel treatments.
Read Article
BEACOPP Regimen Superior to ABVD in Newly Diagnosed, Advanced Hodgkin Lymphoma
By
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
San Diego, CA—In transplant-eligible patients with newly diagnosed, advanced-stage Hodgkin lymphoma, a decision-analytic model showed that chemotherapy with bleomycin, plus etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) maximized life-expectancy and quality-adjusted life expectancy compared with doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD) therapy in the first-line setting, reported Abi Vijenthira, MD, Princess Margaret Cancer Centre, University of Toronto, Canada, at the 2016 American Society of Hematology meeting.
Read Article
American Society of Hematology 2016: Leukemia Highlights
Hematologic Malignancies
,
Leukemia
February 2017, Vol 8, No 1
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
2.
Navigating Care Programs in the Post-OCM era
3.
Why AVBCC?
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2023 - Breast Cancer
AMCP Nexus 2022
ASCO 2022 - Wrap Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
VBCC
Print Edition
VBCC
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
VBCC
's
Privacy Policy
, and
VBCC
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION